A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes

Phase 1

Completed

Brief Summary: This is a prospective, single arm, open-label, single-center pilot study to assess the safety, feasibility, and efficacy of Stem Cell Educator therapy for the treatment of patients with Type 1 Diabetes.

Detailed Description: Our previous work demonstrated that human cord blood-derived multipotent stem cells (CB-SCs) are a unique type of stem cell identified from human cord blood, distinct from other stem cell types including hematopoietic stem cells (HSCs), and mesenchymal stem cells (MSCs). The stem cells and harnessed some of their unique properties with Stem Cell Educator therapy by using CB-SCs in a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with adherent CB-SCs in vitro, and returns the "educated" lymphocytes (but not the CB-SCs) to the patient's circulation . This treatment leads to global immune modulations and immune balance as demonstrated by clinical data and animal studies. The Stem Cell Educator therapy may revolutionize the clinical treatment of diabetes and other immune-related diseases through CB-SCs' immune education and induction of immune balance, without the safety and ethical concerns associated with conventional stem cell-based approaches

Recruitment & Eligibility

Inclusion Criteria

Adult patients >/=18 years
Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes
Must have a blood test confirming the presence of at least one autoantibody to pancreatic islet cells (IAA, IA2, GAD 65, ZnT8)
Fasting C-peptide level > 0.3 ng/ml
Adequate venous access for apheresis
Ability to provide informed consent
Must agree to comply with all study requirements and be willing to complete all study visits

Exclusion Criteria

AST or ALT 2 > x upper limit of normal.
Creatinine > 2.0 mg/dl.
Known coronary artery disease or EKG suggestive of coronary artery disease unless cardiac clearance for apheresis is obtained from a cardiologist.
Known active infection
Pregnancy or breastfeeding mothers
Use of immunosuppressive medication within one month of enrollment including but not limited to prednisone, cyclosporine, tacrolimus, sirolimus, and chemotherapy.
Presence of any other autoimmune diseases (lupus, rheumatoid arthritis, scleroderma, etc.)
Anticoagulation other than ASA.
Hemoglobin < 10 g/dl or platelets < 100 k/ml
Is unable or unwilling to provide informed consent
Presence of any other physical or psychological medical condition that, in the opinion of the investigator, would preclude participation

Arm && Interventions

Group	Intervention	Description
Stem Cell Educator Therapy	Stem Cell Educator Therapy	Patients will have apheresis performed and then have their own blood returned to them with the "educated" lymphocytes

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment Related Adverse Events	12 months	The primary study endpoint will be the occurrence of treatment-related adverse effects. Adverse events that occur during therapy (especially those that necessitate temporary or permanent discontinuation of therapy) and over the 12-month follow-up period will be assessed.

Secondary Outcome Measures